MannKind Corp (MNKD) Stock AnalysisMNKDMannKind Corp

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MannKind Corp (MNKD) is a good buy right now due to its recent FDA approval for the Furoscix autoinjector, which is expected to significantly enhance revenue potential. The current price is $3.19, and the stock has shown a recent 5-day change of +4.93%, indicating positive momentum. Additionally, the gross margin stands at 69% for Q2 2026, which is relatively strong and suggests good profitability potential. However, the main risk is the negative net income reported for Q2 2026, which was -$19 million, indicating ongoing financial challenges that investors should monitor closely.

2 analysts cover MNKD: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.25.